Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.North Park Aesthetics has reached an agreement with Biophysica and Interpharma Praha, pursuant to which North Park has acquired exclusive worldwide rights to develop and commercialize products containing fluridil, a novel antiandrogen for topical administration.
Subscribe to our email newsletter
Under the terms of the agreement, North Park is responsible for worldwide development and commercialization of products containing fluridil for all indications.
North Park also acquired an option to assume existing markets associated with two fluridil-containing products, Eucapil and Care: The Solution For The Face, currently sold outside the US for androgenetic alopecia and cutaneous aging, respectively. In addition to fluridil, Care: The Solution For The Face contains vitamins, resveratrol and other plant extracts.
Fluridil is the primary ingredient in NP-619, North Park’s Phase II product for androgenetic alopecia (pattern baldness).